Related references
Note: Only part of the references are listed.A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer
Delong Meng et al.
ONCOGENE (2023)
JAK-STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States
Laura E. Stevens et al.
CANCER RESEARCH (2023)
Progression after First-Line Cyclin-Dependent Kinase 4/6 Inhibitor Treatment: Analysis of Molecular Mechanisms and Clinical Data
Federica Villa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)
Identification of hub genes associated with EMT-induced chemoresistance in breast cancer using integrated bioinformatics analysis
Bhavjot Kaur et al.
GENE (2022)
Harmine is an effective therapeutic small molecule for the treatment of cardiac hypertrophy
Jie Huang et al.
ACTA PHARMACOLOGICA SINICA (2022)
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story
Viola Cogliati et al.
LIFE-BASEL (2022)
Cellular mechanisms underlying response and resistance to CDK4/6 inhibitors in the treatment of hormone receptor-positive breast cancer
April C. Watt et al.
BREAST CANCER RESEARCH (2022)
Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells
Ryohei Ogata et al.
BREAST CANCER (2021)
Twist1 is required for the development of UVB-induced squamous cell carcinoma
Fernando Eguiarte-Solomon et al.
MOLECULAR CARCINOGENESIS (2021)
Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1
Ebtesam Nafie et al.
PLOS ONE (2021)
Cancer statistics for the year 2020: An overview
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
Aleix Prat et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis
Yong Xia et al.
NATURE COMMUNICATIONS (2021)
Dynamic EMT: a multi-tool for tumor progression
Simone Brabletz et al.
EMBO JOURNAL (2021)
Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.
Massimo Cristofanilli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
CEACAM Gene Family Mutations Associated With Inherited Breast Cancer Risk - A Comparative Oncology Approach to Discovery
Anna L. W. Huskey et al.
FRONTIERS IN GENETICS (2021)
Histone Deacetylase Inhibitor-Induced CDKN2B and CDKN2D Contribute to G2/M Cell Cycle Arrest Incurred by Oxidative Stress in Hepatocellular Carcinoma Cells via Forkhead Box M1 Suppression
Hae-Ahm Lee et al.
JOURNAL OF CANCER (2021)
Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer
James R. Whittle et al.
CLINICAL CANCER RESEARCH (2020)
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors
Masafumi Iida et al.
BREAST CANCER (2020)
Transcriptomic Profiling Identifies Differentially Expressed Genes in Palbociclib-Resistant ER+MCF7 Breast Cancer Cells
Lilibeth Lanceta et al.
GENES (2020)
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (PALOMA-1, TRIO-18)
Richard S. Finn et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
ΔNp63-Regulated Epithelial-to-Mesenchymal Transition State Heterogeneity Confers a Leader-Follower Relationship That Drives Collective Invasion
Jill M. Westcott et al.
CANCER RESEARCH (2020)
Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database
Hong Yang et al.
ONCOLOGY LETTERS (2020)
MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists (vol 8, 1036, 2017)
Cong Lv et al.
NATURE COMMUNICATIONS (2020)
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Jennifer L. Green et al.
MOLECULAR CANCER THERAPEUTICS (2019)
ΔNp63 to TAp63 expression ratio as a potential molecular marker for cervical cancer prognosis (vol 14, e0214867, 2019)
Sunyoung Park et al.
PLOS ONE (2019)
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Keelan Z. Guiley et al.
SCIENCE (2019)
Inhibition of CDK7 overcomes resistance to CDK4/6 inhibitors in hormone receptor positive breast cancer cells
C. Guarducci et al.
CANCER RESEARCH (2019)
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
Renee de Leeuw et al.
CLINICAL CANCER RESEARCH (2018)
Evaluation of Drug Combination Effect Using a Bliss Independence Dose-Response Surface Model
Qin Liu et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2018)
Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer
Sara Redaelli et al.
CANCER RESEARCH (2018)
Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
C. Yang et al.
ONCOGENE (2017)
A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer
Zachary A. Yochum et al.
MOLECULAR CANCER RESEARCH (2017)
Function and Regulation of MicroRNA-31 in Development and Disease
Nadezda A. Stepicheva et al.
MOLECULAR REPRODUCTION AND DEVELOPMENT (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Christopher D. Hart et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer
Xin Zhou et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
Regulatory roles of microRNA-708 and microRNA-31 in proliferation, apoptosis and invasion of colorectal cancer cells
San-Lin Lei et al.
ONCOLOGY LETTERS (2014)
A preliminary study of the relationship between breast cancer metastasis and loss of heterozygosity by using exome sequencing
Hongsheng Li et al.
SCIENTIFIC REPORTS (2014)
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Michael I. Love et al.
GENOME BIOLOGY (2014)
STAR: ultrafast universal RNA-seq aligner
Alexander Dobin et al.
BIOINFORMATICS (2013)
Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis
Jeff H. Tsai et al.
CANCER CELL (2012)
Cyclin D as a therapeutic target in cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2011)
miR-31: a master regulator of metastasis?
Thomas D. Schmittgen
FUTURE ONCOLOGY (2010)
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Xiaohua Su et al.
NATURE (2010)
The Sequence Alignment/Map format and SAMtools
Heng Li et al.
BIOINFORMATICS (2009)
Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer
Y Mironchik et al.
CANCER RESEARCH (2005)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)